Pharmamarketeer
onderzoek

Novartis phase III EXPAND study shows treatment with Mayzent has clinically meaningful positive impact on CPS in patients with SPMS

9 mei 2019
Pharma Biz

Novartis announced a new analysis of the phase III EXPAND study, demonstrating that treatment with Mayzent (siponimod) had a clinically meaningful positive impact on cognitive processing speed (CPS) in patients with SPMS, an important element in cognitive function.

Ook interessant voor je

Medhc-fases-banner
Advertentie(s)